Islek Duygu, Sanchez Travis, Baral Stefan, Brown Carolyn, Caldwell Joanna A, Glick Jennifer L, Nestadt Danielle Friedman, Jones Jeb, Lucas Iaah L, Sarkar Supriya, de Ruiter Annemiek, Sullivan Patrick S, Valentine-Graves Mariah, Winter Savannah, Vannappagari Vani
Rollins School of Public Health, Emory University, Atlanta, Georgia, United States of America.
Johns Hopkins School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.
PLoS One. 2025 Apr 1;20(4):e0320961. doi: 10.1371/journal.pone.0320961. eCollection 2025.
There remains limited information concerning US transfeminine persons preferences across varying PrEP options. We examined PrEP option willingness, preferences, and associated factors among a US nationwide sample of transfeminine persons.
Sexually active transfeminine persons age 15 + were recruited online between June 2022-October 2023 through social media advertisements. Transfeminine persons not diagnosed with HIV were asked about willingness to initiate, and ranked preference, of three PrEP options- daily oral (DO), on-demand, and long-acting injectable (LA-PrEP). Log-binomial models were used to examine PrEP modality willingness and associated sociodemographic and behavioral characteristics.
Among 2657 transfeminine persons not currently using PrEP, 51% reported willingness to start at least one PrEP option. The highest willingness was reported for on-demand PrEP (42.6%), followed by DO (38.1%) and LA PrEP (27.1%). LA PrEP was ranked the most preferred PrEP option among transfeminine persons who reported willingness to start multiple PrEP options (43%, 277/651). Willingness to start on-demand PrEP was higher among participants who were 15-24 years, resided in the South, did not have health insurance, had more than one sex partners and reported prior awareness of on-demand PrEP. Willingness to use DO and LA PrEP was higher among those who had both private and public insurance, reported condomless anal sex, had more than one sex partners and had used non-injection illicit drugs. Additional factors for DO and LA PrEP willingness was residing in the South and prior awareness of LA PrEP, respectively.
Among transfeminine persons, the highest willingness was reported for on-demand PrEP; and LA PrEP was ranked the most preferred option among those who reported willingness to try multiple options. Offering a variety of PrEP options, informed by an understanding of individual preferences and socio-demographic and behavioral differences, can increase overall PrEP uptake and help meet diverse needs of the transfeminine community.
关于美国跨性别女性对不同暴露前预防(PrEP)方案的偏好,现有信息有限。我们在美国全国范围内的跨性别女性样本中,研究了PrEP方案的意愿、偏好及相关因素。
2022年6月至2023年10月期间,通过社交媒体广告在线招募15岁及以上有性行为的跨性别女性。未被诊断出感染艾滋病毒的跨性别女性被问及启动三种PrEP方案(每日口服、按需服用和长效注射)的意愿,并对其偏好进行排序。使用对数二项模型研究PrEP方案的意愿及相关的社会人口学和行为特征。
在2657名目前未使用PrEP的跨性别女性中,51%报告愿意开始至少一种PrEP方案。按需服用PrEP的意愿最高(42.6%),其次是每日口服(38.1%)和长效注射PrEP(27.1%)。在报告愿意开始多种PrEP方案的跨性别女性中,长效注射PrEP被评为最受欢迎的PrEP方案(43%,277/651)。15至24岁、居住在南方、没有医疗保险、有多个性伴侣且之前了解按需服用PrEP的参与者,开始按需服用PrEP的意愿更高。有私人保险和公共保险、报告有无保护肛交、有多个性伴侣且使用过非注射类非法药物的人,使用每日口服和长效注射PrEP的意愿更高。每日口服和长效注射PrEP意愿的其他因素分别是居住在南方和之前了解长效注射PrEP。
在跨性别女性中,按需服用PrEP的意愿最高;长效注射PrEP在报告愿意尝试多种方案的人中被评为最受欢迎的方案。根据对个人偏好以及社会人口学和行为差异的了解,提供多种PrEP方案,可以提高PrEP的总体接受率,并有助于满足跨性别女性群体的多样化需求。